Health Care · Electromedical & Electrotherapeutic Apparatus · Nasdaq · CIK 1484612 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $4.72Day +9.26%Mkt cap $87M1Y −73.8%Off 52W high −74.6%Vol (1Y) 101.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,470 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.6% of sh out |
| Days to cover6.3d |
| 13F net flow (QoQ)+6.93% |
| Top-10 13F concentration73.2% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$117.6M |
| Earnings (TTM)-$74.8M |
| ROE−106.2% |
| Net margin−68.3% |
| ROIC−88.0% |
| Debt / equity0.76× |
| Sales growth 3Y1.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+27.2% |
| 1Y−73.8% |
| 3Y−98.4% |
| 5Y−99.3% |
| Since incept. (ann.)−59.2% |
Total return through 2026-07-28 · series begins 2020-09-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)101.2% |
| Ann. volatility (3Y)116.2% |
| Sharpe (1Y)−0.78 |
| Sharpe (3Y)−0.52 |
| Max drawdown (1Y)−82.5% |
| Max drawdown (3Y)−99.0% |
| Beta (3Y vs SPY)3.30 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 2.7M | $11M | 14.79% | +3.8% |
| BML Capital Management, LLC | 1.9M | $7M | 10.26% | +250.2% |
| BlackRock, Inc. | 1.3M | $5M | 6.81% | −2.0% |
| BANK OF AMERICA CORP /DE/ | 949,397 | $4M | 5.12% | −0.1% |
| PERCEPTIVE ADVISORS LLC | 833,333 | $3M | 4.50% | +0.0% |
| AQR CAPITAL MANAGEMENT LLC | 808,285 | $3M | 4.36% | +348.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 763,822 | $3M | 4.12% | new |
| PFM Health Sciences, LP | 594,630 | $2M | 3.21% | +12.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$1.03 | — | $27.9M | −6.3% |
| 2025-12-31 | 2026-02-11 | — | — | $28.9M | −2.0% |
| 2025-09-30 | 2025-11-10 | −$1.00 | — | $29.4M | +2.7% |
| 2025-06-30 | 2025-08-06 | −$1.04 | — | $31.4M | +14.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 42% · Consumables Product 26% · Service And Other Revenue 17% · Consoles Product 15%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
